Friday, May 20, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Advanced Development of Filovirus and Lassa Fever Vaccines

by Global Biodefense Staff
March 13, 2016

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals for advanced development of multivalent vaccines against Ebola virus, Sudan virus, Marburg virus and Lassa fever.

The effort also seeks to support technical advances in vaccine development for these filoviruses and Lassa virus.

The research and development activities supported through this BAA will allow candidate vaccines to progress through the product development pipeline toward licensure by the FDA.

Activities funded under this Broad Agency Announcement (BAA) funding mechanism may include:

  • Regulatory, clinical, non-clinical, and manufacturing product planning activities
  • Manufacturing and formulation process development
  • Manufacturing, characterization and release of pilot lot and cGMP material
  • Real time and accelerated vaccine stability testing
  • Conduct of non-clinical studies, including all IND-enabling toxicology studies, combination product approvals and multivalent immunogenicity and interference studies, as needed
  • Development, qualification and validation of all necessary assays and reagents
  • Design, conduct, and completion of a Phase 1 or Phase 2 clinical trials
  • Provision of sufficient clinical and non-clinical samples from all studies to NIAID

It is anticipated that multiple cost reimbursement, completion type contracts will be awarded for a five-year period of performance beginning on or about June 2, 2017. NIAID estimates that the average annual total cost (direct and indirect costs combined) is $10.8 million for all awards made under this effort.

The BAA is planned for official release on March 24. Further details are available via Solicitation Number: BAANIHAI2016064.

Tags: BAAEbolaLassa FeverMarburgNIHVaccines

Related Posts

NIH to Further Invest in Point-of-Care Technologies Research Network
Biodetection

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022
U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity
Biosecurity

U.S. Fish and Wildlife Service Opens Grant Program to Shore Up Avian Flu Biosecurity

April 13, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC